Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial"
Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" is a paper indexed in PICO Portal from OpenAlex.
How many citations does Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" have?
Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" has 0 citations in the OpenAlex counts PICO Portal stores.
When was Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" published?
Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" has 2024 year in the PICO Portal index.
What is the open-access status of Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial"?
Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" has closed oa status in the PICO Portal index.
What is the DOI of Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial"?
The DOI for Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" is on the source record.
What is the OpenAlex record for Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial"?
The OpenAlex for Author response for "<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial" is on the source record.